20.17
前日終値:
$20.43
開ける:
$20.54
24時間の取引高:
164.01K
Relative Volume:
0.84
時価総額:
$360.49M
収益:
$116.88M
当期純損益:
$-25.09M
株価収益率:
-144.07
EPS:
-0.14
ネットキャッシュフロー:
$-20.74M
1週間 パフォーマンス:
+7.29%
1か月 パフォーマンス:
+8.27%
6か月 パフォーマンス:
-9.02%
1年 パフォーマンス:
+85.05%
Rigel Pharmaceuticals Stock (RIGL) Company Profile
名前
Rigel Pharmaceuticals
セクター
電話
650-624-1100
住所
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
RIGL を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
RIGL
Rigel Pharmaceuticals
|
20.17 | 365.13M | 116.88M | -25.09M | -20.74M | -0.14 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-04-03 | 再開されました | Piper Sandler | Neutral |
2022-06-09 | ダウングレード | Citigroup | Buy → Neutral |
2022-06-08 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2022-06-08 | ダウングレード | Piper Sandler | Overweight → Neutral |
2022-03-23 | 開始されました | B. Riley Securities | Neutral |
2020-11-09 | ダウングレード | JP Morgan | Overweight → Neutral |
2019-11-15 | 再開されました | Cantor Fitzgerald | Overweight |
2019-09-26 | 再開されました | JP Morgan | Overweight |
2019-03-01 | 繰り返されました | Cantor Fitzgerald | Overweight |
2018-08-27 | 開始されました | Citigroup | Buy |
2018-05-02 | 繰り返されました | Cantor Fitzgerald | Overweight |
2017-12-21 | 再開されました | Piper Jaffray | Overweight |
2017-12-15 | 開始されました | Cantor Fitzgerald | Overweight |
2017-11-06 | 再開されました | H.C. Wainwright | Buy |
2017-03-09 | 繰り返されました | H.C. Wainwright | Buy |
2016-08-31 | 繰り返されました | H.C. Wainwright | Buy |
2016-08-30 | 繰り返されました | Piper Jaffray | Overweight |
2016-07-13 | 開始されました | H.C. Wainwright | Buy |
2016-06-13 | 開始されました | Piper Jaffray | Overweight |
2016-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
2013-04-08 | 繰り返されました | Stifel | Buy |
2012-11-29 | 開始されました | UBS | Neutral |
2012-11-06 | 繰り返されました | Oppenheimer | Outperform |
2012-03-26 | 開始されました | Canaccord Genuity | Hold |
2010-12-10 | ダウングレード | MP Advisors | Outperform → Market Perform |
すべてを表示
Rigel Pharmaceuticals (RIGL) 最新ニュース
Eli Lilly and Rigel Pharmaceuticals: Promising Advances in Rheumatoid Arthritis Treatment - TipRanks
Will Rigel Pharmaceuticals Inc. stock benefit from AI tech trendsHigh-impact stock picks - jammulinksnews.com
Is Rigel Pharmaceuticals Inc. a good long term investmentAccelerated wealth building - PrintWeekIndia
What institutions are buying Rigel Pharmaceuticals Inc. stock nowHigh-margin investment plays - jammulinksnews.com
What analysts say about Rigel Pharmaceuticals Inc. stockStrongest growth potential - PrintWeekIndia
What drives Rigel Pharmaceuticals Inc. stock priceHigh-margin investment plays - Autocar Professional
Institutional investors have a lot riding on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) with 65% ownership - simplywall.st
Eli Lilly and Rigel Pharmaceuticals Advance Rheumatoid Arthritis Study with LY3871801 - TipRanks
Rigel Pharmaceuticals Inc. Stock Analysis and ForecastFastest-growing stock picks - jammulinksnews.com
(RIGL) Proactive Strategies - news.stocktradersdaily.com
What makes Rigel Pharmaceuticals Inc. stock price move sharplyHigh Potential Stock Ideas - newser.com
Why Rigel Pharmaceuticals Inc. stock attracts strong analyst attentionFree Top-Rated Stock Analysis - Newser
H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL) - Insider Monkey
(RIGL) Long Term Investment Analysis - news.stocktradersdaily.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | RIGL Stock News - GuruFocus
Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NA - GuruFocus
Recent 11% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 112% over 1 year - simplywall.st
Rigel Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential By Investing.com - Investing.com Canada
Rigel Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential - Investing.com
High-grade Glioma Market Expected to Experience Major Growth by 2034, According to DelveInsight | Rigel Pharma, Orbus Therapeutics, BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, CNS Pharma - Barchart.com
Wellington Management Group LLP Makes New Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by Nuveen Asset Management LLC - Defense World
Two Sigma Investments LP Makes New $1.03 Million Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals at Jefferies Conference: Strategic Growth and Innovation By Investing.com - Investing.com Nigeria
Millennium Management LLC Takes $1.19 Million Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals at Jefferies Conference: Strategic Growth and Innovation - Investing.com
Rigel Pharma To Present At Jefferies Global Healthcare Conference; Webcast At 12:50 PM ET - Nasdaq
Deutsche Bank AG Increases Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of “Hold” from Brokerages - Defense World
Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now? - Yahoo Finance
Rigel to Present at the Jefferies Global Healthcare Conference - StreetInsider
Director Lapointe Anthony Gregg was granted 2,500 shares, increasing direct ownership by 25% to 12,500 units (SEC Form 4) - Quantisnow
Director Hannah Alison L. was granted 2,500 shares, increasing direct ownership by 31% to 10,625 units (SEC Form 4) - Quantisnow
Wall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High? - sharewise
Rigel Pharmaceuticals (RIGL) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):